Pulmonx (LUNG) Financials

$1.34 +0.01 (+0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$1.34 0.00 (0.00%)

As of 04:10 PM Eastern

Annual Income Statements for Pulmonx

This table shows Pulmonx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-59	-61	-56
Consolidated Net Income / (Loss)	-59	-61	-56
Net Income / (Loss) Continuing Operations	-59	-61	-56
Total Pre-Tax Income	-59	-60	-56
Total Operating Income	-59	-62	-58
Total Gross Profit	40	51	62
Total Revenue	54	69	84
Operating Revenue	54	69	84
Total Cost of Revenue	14	18	22
Operating Cost of Revenue	14	18	22
Total Operating Expenses	99	113	120
Selling, General & Admin Expense	83	95	102
Research & Development Expense	15	18	18
Total Other Income / (Expense), net	0.07	1.66	1.81
Interest Expense	1.07	3.23	3.51
Interest & Investment Income	1.53	5.57	5.06
Other Income / (Expense), net	-0.40	-0.67	0.26
Income Tax Expense	0.35	0.57	0.50
Basic Earnings per Share	($1.59)	($1.60)	($1.44)
Weighted Average Basic Shares Outstanding	37.10M	37.97M	39.11M
Diluted Earnings per Share	($1.59)	($1.60)	($1.44)
Weighted Average Diluted Shares Outstanding	37.10M	37.97M	39.11M
Weighted Average Basic & Diluted Shares Outstanding	37.65M	38.54M	39.80M

This table shows Pulmonx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-14	-14	-16	-16	-15	-14	-14	-15	-14	-13
Consolidated Net Income / (Loss)	-14	-14	-16	-16	-15	-14	-14	-15	-14	-13
Net Income / (Loss) Continuing Operations	-14	-14	-16	-16	-15	-14	-14	-15	-14	-13
Total Pre-Tax Income	-14	-14	-16	-16	-15	-14	-14	-15	-14	-13
Total Operating Income	-14	-15	-16	-16	-15	-14	-15	-16	-14	-13
Total Gross Profit	10	11	11	13	13	14	14	15	15	18
Total Revenue	14	15	15	17	18	19	19	21	20	24
Operating Revenue	14	15	15	17	18	19	19	21	20	24
Total Cost of Revenue	3.35	4.24	3.95	4.46	4.64	4.88	4.78	5.48	5.36	6.18
Operating Cost of Revenue	3.35	4.24	3.95	4.46	4.64	4.88	4.78	5.48	5.36	6.18
Total Operating Expenses	24	26	27	29	28	28	29	31	29	31
Selling, General & Admin Expense	20	22	23	23	24	24	24	25	25	27
Research & Development Expense	4.37	3.90	4.25	5.71	4.22	3.90	4.21	5.62	3.74	4.00
Total Other Income / (Expense), net	-0.24	0.59	0.66	0.38	0.34	0.28	0.97	0.38	0.18	0.28
Interest Expense	0.29	0.36	0.57	0.86	0.89	0.90	0.88	0.89	0.89	0.84
Interest & Investment Income	0.48	0.75	1.13	1.41	1.49	1.54	1.44	1.31	1.27	1.05
Other Income / (Expense), net	-0.43	0.20	0.11	-0.16	-0.26	-0.36	0.42	-0.04	-0.20	0.08
Income Tax Expense	0.00	0.25	0.12	0.14	0.06	0.25	0.19	0.08	0.19	0.04
Basic Earnings per Share	($0.38)	($0.38)	($0.42)	($0.43)	($0.39)	($0.36)	($0.36)	($0.39)	($0.36)	($0.33)
Weighted Average Basic Shares Outstanding	37.19M	37.10M	37.57M	37.82M	38.12M	37.97M	38.64M	38.94M	39.28M	39.11M
Diluted Earnings per Share	($0.38)	($0.38)	($0.42)	($0.43)	($0.39)	($0.36)	($0.36)	($0.39)	($0.36)	($0.33)
Weighted Average Diluted Shares Outstanding	37.19M	37.10M	37.57M	37.82M	38.12M	37.97M	38.64M	38.94M	39.28M	39.11M
Weighted Average Basic & Diluted Shares Outstanding	37.41M	37.65M	37.75M	38.03M	38.31M	38.54M	38.82M	39.15M	39.49M	39.80M

This table details how cash moves in and out of Pulmonx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-47	-18	-13
Net Cash From Operating Activities	-45	-38	-32
Net Cash From Continuing Operating Activities	-45	-38	-32
Net Income / (Loss) Continuing Operations	-59	-61	-56
Consolidated Net Income / (Loss)	-59	-61	-56
Depreciation Expense	1.51	1.55	1.49
Amortization Expense	-0.15	-0.98	-1.56
Non-Cash Adjustments To Reconcile Net Income	19	25	27
Changes in Operating Assets and Liabilities, net	-7.01	-2.56	-1.70
Net Cash From Investing Activities	-4.23	-2.01	17
Net Cash From Continuing Investing Activities	-4.23	-2.01	17
Purchase of Property, Plant & Equipment	-1.32	-0.81	-1.45
Purchase of Investments	-47	-46	-28
Sale and/or Maturity of Investments	44	45	47
Net Cash From Financing Activities	2.42	21	1.36
Net Cash From Continuing Financing Activities	2.42	21	1.36
Repayment of Debt	-0.14	-0.09	-0.10
Issuance of Debt	0.00	20	0.00
Issuance of Common Equity	1.94	1.18	1.24
Other Financing Activities, net	0.64	0.31	0.22
Effect of Exchange Rate Changes	0.15	0.03	0.08
Cash Interest Paid	0.85	2.98	3.48
Cash Income Taxes Paid	0.40	0.47	0.56

This table details how cash moves in and out of Pulmonx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-9.55	-11	8.67	-8.59	-6.87	-11	-13	-6.67	-0.15	7.59
Net Cash From Operating Activities	-11	-9.81	-13	-7.89	-8.63	-8.45	-12	-5.77	-7.24	-6.73
Net Cash From Continuing Operating Activities	-11	-9.81	-13	-7.89	-8.63	-8.45	-12	-5.77	-7.24	-6.73
Net Income / (Loss) Continuing Operations	-14	-14	-16	-16	-15	-14	-14	-15	-14	-13
Consolidated Net Income / (Loss)	-14	-14	-16	-16	-15	-14	-14	-15	-14	-13
Depreciation Expense	0.38	0.39	0.44	0.41	0.42	0.29	0.42	0.40	0.38	0.29
Amortization Expense	-0.06	-0.14	-0.19	-0.22	-0.25	-0.31	-0.38	-0.46	-0.39	-0.33
Non-Cash Adjustments To Reconcile Net Income	5.21	5.05	5.57	6.64	7.13	5.89	6.54	8.31	6.10	5.69
Changes in Operating Assets and Liabilities, net	-2.05	-0.82	-2.59	1.48	-1.02	-0.42	-4.63	1.31	0.83	0.79
Net Cash From Investing Activities	0.04	-0.73	0.57	-0.81	0.99	-2.76	-2.51	-0.84	6.75	14
Net Cash From Continuing Investing Activities	0.04	-0.73	0.57	-0.81	0.99	-2.76	-2.51	-0.84	6.75	14
Purchase of Property, Plant & Equipment	-0.28	-0.18	-0.06	-0.05	-0.49	-0.20	-0.45	-0.47	-0.42	-0.11
Purchase of Investments	-15	-10	-13	-13	-16	-4.81	-14	-7.03	-5.58	-1.49
Sale and/or Maturity of Investments	15	9.75	14	12	17	2.25	12	6.67	13	16
Net Cash From Financing Activities	0.91	0.07	21	0.09	0.57	0.02	0.86	-0.02	0.46	0.06
Net Cash From Continuing Financing Activities	0.91	0.07	21	0.09	0.57	0.02	0.86	-0.02	0.46	0.06
Repayment of Debt	-	-0.10	-	-	-	-0.05	-	-	-	-0.05
Issuance of Common Equity	0.83	-	0.68	-	0.51	-	0.81	-	0.43	0.00
Other Financing Activities, net	0.07	0.19	0.04	0.14	0.06	0.06	0.06	0.02	0.03	0.11
Effect of Exchange Rate Changes	0.19	-0.20	0.02	0.02	0.20	-0.21	0.05	-0.05	-0.12	0.19
Cash Interest Paid	0.25	0.22	0.36	0.88	0.87	0.88	0.88	0.90	0.88	0.82
Cash Income Taxes Paid	0.11	0.06	0.09	0.11	0.16	0.10	0.17	0.11	0.19	0.10

This table presents Pulmonx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	194	178	163
Total Current Assets	169	150	136
Cash & Equivalents	102	84	71
Restricted Cash	0.23	0.24	0.26
Short-Term Investments	39	34	31
Accounts Receivable	8.68	12	13
Inventories, net	15	17	17
Prepaid Expenses	4.34	4.24	4.47
Plant, Property, & Equipment, net	4.69	4.03	2.91
Total Noncurrent Assets	20	23	24
Long-Term Investments	5.92	14	0.00
Goodwill	2.33	2.33	2.33
Intangible Assets	0.15	0.03	0.00
Other Noncurrent Operating Assets	12	6.58	21
Total Liabilities & Shareholders' Equity	194	178	163
Total Liabilities	40	59	77
Total Current Liabilities	18	23	24
Short-Term Debt	0.09	2.16	3.18
Accounts Payable	1.76	1.50	3.83
Accrued Expenses	13	16	16
Current Deferred Revenue	0.12	0.10	0.14
Current Deferred & Payable Income Tax Liabilities	0.02	0.09	0.05
Other Current Liabilities	3.23	3.07	0.78
Total Noncurrent Liabilities	21	36	53
Long-Term Debt	17	35	34
Noncurrent Deferred & Payable Income Tax Liabilities	0.09	0.11	0.09
Other Noncurrent Operating Liabilities	3.85	1.11	19
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	154	118	86
Total Preferred & Common Equity	154	118	86
Preferred Stock	0.00	0.00	0.00
Total Common Equity	154	118	86
Common Stock	503	527	551
Retained Earnings	-350	-411	-468
Accumulated Other Comprehensive Income / (Loss)	1.58	2.64	2.11

This table presents Pulmonx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	202	201	193	185	165	173	167
Total Current Assets	183	181	164	147	148	146	141
Cash & Equivalents	112	110	102	95	70	63	63
Restricted Cash	0.23	0.23	0.47	0.24	0.24	0.26	0.26
Short-Term Investments	44	42	34	22	46	51	44
Accounts Receivable	7.22	8.17	8.94	10	11	11	12
Inventories, net	16	16	16	16	17	17	17
Prepaid Expenses	3.19	4.47	4.23	4.42	3.82	3.30	4.26
Plant, Property, & Equipment, net	4.92	4.49	4.22	4.07	4.22	2.83	2.98
Total Noncurrent Assets	14	15	24	34	12	24	23
Long-Term Investments	0.00	2.64	12	23	4.29	0.00	0.00
Goodwill	2.33	2.33	2.33	2.33	2.33	2.33	2.33
Intangible Assets	0.19	0.12	0.09	0.06	0.00	0.00	0.00
Other Noncurrent Operating Assets	12	10	9.59	7.92	5.80	21	21
Total Liabilities & Shareholders' Equity	202	201	193	185	165	173	167
Total Liabilities	39	57	59	59	54	71	73
Total Current Liabilities	22	17	20	20	21	16	18
Short-Term Debt	5.04	0.09	0.09	0.09	5.23	0.09	0.10
Accounts Payable	2.65	2.89	2.38	3.19	3.13	3.18	4.58
Accrued Expenses	11	11	14	14	10	12	13
Current Deferred Revenue	0.11	0.11	0.10	0.09	0.11	0.11	0.11
Current Deferred & Payable Income Tax Liabilities	0.00	0.06	0.04	0.00	0.07	0.07	0.07
Other Current Liabilities	3.15	3.30	3.35	3.44	2.69	1.07	0.66
Total Noncurrent Liabilities	17	40	40	39	33	55	55
Long-Term Debt	12	37	37	37	32	37	37
Noncurrent Deferred & Payable Income Tax Liabilities	0.05	0.07	0.09	0.10	0.14	0.12	0.13
Other Noncurrent Operating Liabilities	4.64	3.02	2.40	1.54	0.65	18	18
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	163	144	134	126	110	101	94
Total Preferred & Common Equity	163	144	134	126	110	101	94
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	163	144	134	126	110	101	94
Common Stock	498	508	514	521	533	539	546
Retained Earnings	-336	-366	-382	-397	-425	-440	-454
Accumulated Other Comprehensive Income / (Loss)	1.40	1.82	1.96	1.94	1.96	1.97	2.53

This table displays calculated financial ratios and metrics derived from Pulmonx's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	10.84%	27.98%	22.01%
EBITDA Growth	-23.07%	-7.58%	7.28%
EBIT Growth	-23.27%	-6.06%	8.24%
NOPAT Growth	-23.96%	-5.62%	6.83%
Net Income Growth	-21.09%	-3.26%	7.31%
EPS Growth	-17.78%	-0.63%	10.00%
Operating Cash Flow Growth	-8.93%	16.58%	16.15%
Free Cash Flow Firm Growth	-10.83%	5.10%	12.37%
Invested Capital Growth	22.52%	-0.87%	-10.84%
Revenue Q/Q Growth	3.31%	5.94%	5.66%
EBITDA Q/Q Growth	-3.30%	-0.20%	1.59%
EBIT Q/Q Growth	-2.92%	0.24%	1.60%
NOPAT Q/Q Growth	-4.01%	1.13%	0.86%
Net Income Q/Q Growth	-2.22%	0.65%	1.25%
EPS Q/Q Growth	-1.27%	1.23%	2.04%
Operating Cash Flow Q/Q Growth	1.97%	3.48%	5.17%
Free Cash Flow Firm Q/Q Growth	0.47%	-0.08%	7.49%
Invested Capital Q/Q Growth	1.28%	3.61%	-8.11%
Profitability Metrics	-	-	-
Gross Margin	74.29%	73.90%	74.00%
EBITDA Margin	-107.47%	-90.33%	-68.65%
Operating Margin	-109.27%	-90.19%	-68.87%
EBIT Margin	-110.01%	-91.17%	-68.56%
Profit (Net Income) Margin	-109.80%	-88.60%	-67.30%
Tax Burden Percent	100.60%	100.95%	100.89%
Interest Burden Percent	99.22%	96.27%	97.29%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-188.03%	-181.14%	-179.21%
ROIC Less NNEP Spread (ROIC-NNEP)	-176.26%	-165.56%	-159.09%
Return on Net Nonoperating Assets (RNNOA)	154.10%	136.46%	123.96%
Return on Equity (ROE)	-33.94%	-44.68%	-55.25%
Cash Return on Invested Capital (CROIC)	-208.27%	-180.27%	-167.76%
Operating Return on Assets (OROA)	-27.53%	-33.71%	-33.73%
Return on Assets (ROA)	-27.48%	-32.76%	-33.11%
Return on Common Equity (ROCE)	-33.94%	-44.68%	-55.25%
Return on Equity Simple (ROE_SIMPLE)	-38.26%	-51.42%	-65.72%
Net Operating Profit after Tax (NOPAT)	-41	-43	-40
NOPAT Margin	-76.49%	-63.13%	-48.21%
Net Nonoperating Expense Percent (NNEP)	-11.78%	-15.58%	-20.12%
Return On Investment Capital (ROIC_SIMPLE)	-	-27.87%	-32.84%
Cost of Revenue to Revenue	25.71%	26.10%	26.00%
SG&A Expenses to Revenue	154.87%	137.76%	121.90%
R&D to Revenue	28.69%	26.33%	20.97%
Operating Expenses to Revenue	183.56%	164.09%	142.86%
Earnings before Interest and Taxes (EBIT)	-59	-63	-57
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-58	-62	-58
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.05	4.13	3.12
Price to Tangible Book Value (P/TBV)	2.08	4.21	3.21
Price to Revenue (P/Rev)	5.88	7.11	3.20
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	7.71	16.53	9.58
Enterprise Value to Revenue (EV/Rev)	3.45	5.74	2.43
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.11	0.31	0.43
Long-Term Debt to Equity	0.11	0.30	0.40
Financial Leverage	-0.87	-0.82	-0.78
Leverage Ratio	1.24	1.36	1.67
Compound Leverage Factor	1.23	1.31	1.62
Debt to Total Capital	10.11%	23.94%	30.23%
Short-Term Debt to Total Capital	0.05%	1.39%	2.58%
Long-Term Debt to Total Capital	10.06%	22.56%	27.65%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	89.89%	76.06%	69.77%
Debt to EBITDA	-0.30	-0.60	-0.65
Net Debt to EBITDA	2.25	1.52	1.12
Long-Term Debt to EBITDA	-0.30	-0.57	-0.59
Debt to NOPAT	-0.42	-0.86	-0.92
Net Debt to NOPAT	3.17	2.18	1.60
Long-Term Debt to NOPAT	-0.42	-0.81	-0.84
Altman Z-Score	2.44	1.77	-1.76
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.14	6.50	5.58
Quick Ratio	8.10	5.58	4.69
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-45	-43	-38
Operating Cash Flow to CapEx	-3,420.56%	-4,660.47%	-2,179.47%
Free Cash Flow to Firm to Interest Expense	-42.65	-13.35	-10.78
Operating Cash Flow to Interest Expense	-42.29	-11.64	-8.99
Operating Cash Flow Less CapEx to Interest Expense	-43.53	-11.89	-9.41
Efficiency Ratios	-	-	-
Asset Turnover	0.25	0.37	0.49
Accounts Receivable Turnover	7.04	6.61	6.64
Inventory Turnover	0.89	1.15	1.29
Fixed Asset Turnover	11.29	15.75	24.16
Accounts Payable Turnover	8.26	11.01	8.18
Days Sales Outstanding (DSO)	51.83	55.23	54.94
Days Inventory Outstanding (DIO)	408.06	318.78	281.93
Days Payable Outstanding (DPO)	44.18	33.14	44.59
Cash Conversion Cycle (CCC)	415.70	340.87	292.27
Capital & Investment Metrics	-	-	-
Invested Capital	24	24	21
Invested Capital Turnover	2.46	2.87	3.72
Increase / (Decrease) in Invested Capital	4.42	-0.21	-2.58
Enterprise Value (EV)	185	394	204
Market Capitalization	315	488	268
Book Value per Share	$4.12	$3.09	$2.17
Tangible Book Value per Share	$4.05	$3.03	$2.11
Total Capital	171	156	123
Total Debt	17	37	37
Total Long-Term Debt	17	35	34
Net Debt	-130	-94	-65
Capital Expenditures (CapEx)	1.32	0.81	1.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)	9.18	12	13
Debt-free Net Working Capital (DFNWC)	151	129	115
Net Working Capital (NWC)	150	127	112
Net Nonoperating Expense (NNE)	18	17	16
Net Nonoperating Obligations (NNO)	-130	-94	-65
Total Depreciation and Amortization (D&A)	1.37	0.57	-0.07
Debt-free, Cash-free Net Working Capital to Revenue	17.11%	17.59%	15.81%
Debt-free Net Working Capital to Revenue	280.55%	188.45%	137.23%
Net Working Capital to Revenue	280.39%	185.31%	133.44%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.59)	($1.60)	($1.44)
Adjusted Weighted Average Basic Shares Outstanding	37.10M	37.97M	39.11M
Adjusted Diluted Earnings per Share	($1.59)	($1.60)	($1.44)
Adjusted Weighted Average Diluted Shares Outstanding	37.10M	37.97M	39.11M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.65M	38.54M	39.80M
Normalized Net Operating Profit after Tax (NOPAT)	-41	-43	-40
Normalized NOPAT Margin	-76.49%	-63.13%	-48.21%
Pre Tax Income Margin	-109.15%	-87.76%	-66.71%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-55.38	-19.37	-16.38
NOPAT to Interest Expense	-38.50	-13.41	-11.52
EBIT Less CapEx to Interest Expense	-56.61	-19.62	-16.79
NOPAT Less CapEx to Interest Expense	-39.74	-13.66	-11.93
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.05%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Pulmonx's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1.82%	12.53%	34.77%	23.25%	30.85%	24.98%	29.71%	20.87%	15.39%	23.28%
EBITDA Growth	-43.61%	-14.93%	-5.16%	-15.69%	-8.77%	-0.88%	12.29%	4.22%	6.05%	6.49%
EBIT Growth	-43.21%	-13.15%	-3.98%	-13.89%	-7.48%	1.03%	13.33%	5.69%	7.18%	6.56%
NOPAT Growth	-42.71%	-18.28%	-4.67%	-14.07%	-8.94%	4.83%	11.37%	4.97%	6.90%	3.61%
Net Income Growth	-39.20%	-9.82%	-0.20%	-10.62%	-5.14%	2.77%	13.31%	5.37%	5.07%	5.13%
EPS Growth	-35.71%	-5.56%	2.33%	-7.50%	-2.63%	5.26%	14.29%	9.30%	7.69%	8.33%
Operating Cash Flow Growth	-28.53%	8.45%	15.85%	17.49%	19.29%	13.84%	6.71%	26.88%	16.04%	20.35%
Free Cash Flow Firm Growth	3.94%	11.53%	35.04%	29.40%	38.08%	34.94%	16.62%	5.51%	-1.30%	28.59%
Invested Capital Growth	35.48%	22.52%	11.42%	2.47%	-3.10%	-0.87%	6.19%	2.01%	0.54%	-10.84%
Revenue Q/Q Growth	-3.21%	14.24%	-5.77%	18.29%	2.76%	9.11%	-2.20%	10.23%	-1.91%	16.57%
EBITDA Q/Q Growth	1.04%	-0.98%	-13.19%	-2.28%	6.96%	6.34%	1.59%	-11.69%	8.73%	6.78%
EBIT Q/Q Growth	1.46%	-0.44%	-12.94%	-1.90%	7.01%	7.52%	1.09%	-10.88%	8.48%	6.91%
NOPAT Q/Q Growth	3.33%	-5.00%	-12.12%	-0.24%	7.68%	8.28%	-4.43%	-7.47%	9.56%	5.04%
Net Income Q/Q Growth	3.20%	-0.78%	-11.04%	-2.11%	8.00%	6.79%	1.00%	-11.47%	7.71%	6.85%
EPS Q/Q Growth	5.00%	0.00%	-10.53%	-2.38%	9.30%	7.69%	0.00%	-8.33%	7.69%	8.33%
Operating Cash Flow Q/Q Growth	-11.74%	8.24%	-28.94%	37.59%	-9.31%	2.05%	-39.60%	51.08%	-25.51%	7.07%
Free Cash Flow Firm Q/Q Growth	6.57%	8.21%	3.84%	14.39%	18.05%	3.55%	-23.24%	2.99%	12.15%	32.01%
Invested Capital Q/Q Growth	5.20%	1.28%	6.06%	-9.31%	-0.52%	3.61%	13.60%	-12.88%	-1.95%	-8.11%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	75.19%	72.51%	72.85%	74.06%	73.74%	74.70%	74.67%	73.65%	73.70%	74.02%
EBITDA Margin	-103.99%	-91.92%	-110.41%	-95.46%	-86.44%	-74.19%	-74.65%	-75.64%	-70.38%	-56.28%
Operating Margin	-103.18%	-94.83%	-112.83%	-95.61%	-85.90%	-72.21%	-77.10%	-75.17%	-69.30%	-56.46%
EBIT Margin	-106.38%	-93.52%	-112.09%	-96.55%	-87.38%	-74.06%	-74.90%	-75.34%	-70.29%	-56.13%
Profit (Net Income) Margin	-104.96%	-92.60%	-109.12%	-94.19%	-84.33%	-72.04%	-72.92%	-73.74%	-69.38%	-55.44%
Tax Burden Percent	100.00%	101.75%	100.79%	100.87%	100.40%	101.82%	101.37%	100.55%	101.38%	100.29%
Interest Burden Percent	98.67%	97.30%	96.59%	96.71%	96.13%	95.54%	96.05%	97.35%	97.36%	98.48%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-181.88%	-163.18%	-187.48%	-177.73%	-166.80%	-145.03%	-149.89%	-172.55%	-166.82%	-146.92%
ROIC Less NNEP Spread (ROIC-NNEP)	-179.16%	-160.51%	-184.32%	-174.13%	-163.27%	-141.34%	-146.34%	-167.89%	-161.92%	-142.16%
Return on Net Nonoperating Assets (RNNOA)	158.99%	140.33%	156.98%	148.14%	136.89%	116.49%	116.11%	134.55%	127.92%	110.76%
Return on Equity (ROE)	-22.90%	-22.85%	-30.50%	-29.58%	-29.91%	-28.54%	-33.78%	-38.01%	-38.90%	-36.15%
Cash Return on Invested Capital (CROIC)	-221.45%	-208.27%	-182.63%	-190.60%	-184.51%	-180.27%	-165.99%	-179.61%	-177.22%	-167.76%
Operating Return on Assets (OROA)	-24.61%	-23.41%	-30.35%	-28.86%	-29.26%	-27.38%	-29.89%	-31.55%	-31.63%	-27.62%
Return on Assets (ROA)	-24.29%	-23.17%	-29.54%	-28.15%	-28.24%	-26.64%	-29.10%	-30.88%	-31.22%	-27.27%
Return on Common Equity (ROCE)	-22.90%	-22.85%	-30.50%	-29.58%	-29.91%	-28.54%	-33.78%	-38.01%	-38.90%	-36.15%
Return on Equity Simple (ROE_SIMPLE)	-35.26%	0.00%	-40.96%	-45.17%	-48.70%	0.00%	-53.15%	-57.19%	-60.80%	0.00%
Net Operating Profit after Tax (NOPAT)	-9.75	-10	-11	-12	-11	-9.74	-10	-11	-9.89	-9.39
NOPAT Margin	-72.22%	-66.38%	-78.98%	-66.93%	-60.13%	-50.54%	-53.97%	-52.62%	-48.51%	-39.52%
Net Nonoperating Expense Percent (NNEP)	-2.72%	-2.66%	-3.15%	-3.60%	-3.53%	-3.69%	-3.54%	-4.66%	-4.90%	-4.76%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-6.26%	-	-	-	-7.64%
Cost of Revenue to Revenue	24.81%	27.49%	27.15%	25.94%	26.26%	25.30%	25.33%	26.35%	26.30%	25.98%
SG&A Expenses to Revenue	146.03%	142.03%	156.42%	136.46%	135.75%	126.69%	129.44%	121.80%	124.64%	113.64%
R&D to Revenue	32.34%	25.30%	29.26%	33.21%	23.89%	20.21%	22.33%	27.02%	18.36%	16.84%
Operating Expenses to Revenue	178.37%	167.33%	185.68%	169.67%	159.64%	146.90%	151.77%	148.82%	143.01%	130.47%
Earnings before Interest and Taxes (EBIT)	-14	-14	-16	-17	-15	-14	-14	-16	-14	-13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-14	-14	-16	-16	-15	-14	-14	-16	-14	-13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.80	2.05	2.92	3.69	3.12	4.13	3.21	2.43	3.46	3.12
Price to Tangible Book Value (P/TBV)	3.86	2.08	2.98	3.76	3.18	4.21	3.28	2.49	3.54	3.21
Price to Revenue (P/Rev)	11.95	5.88	7.33	8.16	6.06	7.11	4.87	3.21	4.09	3.20
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	20.27	7.71	11.86	16.61	12.61	16.53	10.04	7.14	10.97	9.58
Enterprise Value to Revenue (EV/Rev)	9.26	3.45	5.27	6.33	4.48	5.74	3.72	2.20	3.20	2.43
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.11	0.11	0.26	0.28	0.30	0.31	0.34	0.37	0.40	0.43
Long-Term Debt to Equity	0.08	0.11	0.26	0.28	0.30	0.30	0.29	0.37	0.40	0.40
Financial Leverage	-0.89	-0.87	-0.85	-0.85	-0.84	-0.82	-0.79	-0.80	-0.79	-0.78
Leverage Ratio	1.23	1.24	1.30	1.33	1.34	1.36	1.44	1.56	1.60	1.67
Compound Leverage Factor	1.21	1.20	1.26	1.28	1.29	1.30	1.38	1.51	1.56	1.64
Debt to Total Capital	9.61%	10.11%	20.57%	21.75%	22.85%	23.94%	25.20%	26.88%	28.39%	30.23%
Short-Term Debt to Total Capital	2.79%	0.05%	0.05%	0.05%	0.06%	1.39%	3.54%	0.07%	0.08%	2.58%
Long-Term Debt to Total Capital	6.82%	10.06%	20.52%	21.70%	22.80%	22.56%	21.66%	26.82%	28.31%	27.65%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	90.39%	89.89%	79.43%	78.25%	77.15%	76.06%	74.80%	73.12%	71.61%	69.77%
Debt to EBITDA	-0.31	-0.30	-0.64	-0.61	-0.60	-0.60	-0.62	-0.63	-0.64	-0.65
Net Debt to EBITDA	2.50	2.25	2.03	1.83	1.66	1.52	1.39	1.31	1.21	1.12
Long-Term Debt to EBITDA	-0.22	-0.30	-0.64	-0.61	-0.60	-0.57	-0.53	-0.63	-0.64	-0.59
Debt to NOPAT	-0.44	-0.42	-0.90	-0.87	-0.85	-0.86	-0.89	-0.90	-0.91	-0.92
Net Debt to NOPAT	3.54	3.17	2.85	2.58	2.34	2.18	1.98	1.87	1.74	1.60
Long-Term Debt to NOPAT	-0.31	-0.42	-0.89	-0.86	-0.85	-0.81	-0.76	-0.89	-0.91	-0.84
Altman Z-Score	8.27	3.20	2.85	3.18	1.87	2.67	1.41	-0.46	-0.08	-0.86
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.44	9.14	10.62	8.42	7.19	6.50	6.95	8.97	7.70	5.58
Quick Ratio	7.57	8.10	9.43	7.38	6.18	5.58	5.95	7.71	6.53	4.69
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-16	-15	-14	-12	-9.89	-9.54	-12	-11	-10	-6.81
Operating Cash Flow to CapEx	-3,830.47%	-5,571.59%	-20,727.87%	-14,612.96%	-1,753.25%	-4,224.50%	-2,615.30%	-1,230.28%	-1,740.87%	-6,063.06%
Free Cash Flow to Firm to Interest Expense	-55.83	-40.83	-24.68	-13.96	-11.07	-10.55	-13.31	-12.80	-11.24	-8.09
Operating Cash Flow to Interest Expense	-37.37	-27.31	-22.14	-9.13	-9.66	-9.35	-13.36	-6.48	-8.13	-7.99
Operating Cash Flow Less CapEx to Interest Expense	-38.34	-27.81	-22.25	-9.20	-10.21	-9.57	-13.87	-7.00	-8.59	-8.12
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.23	0.25	0.27	0.30	0.33	0.37	0.40	0.42	0.45	0.49
Accounts Receivable Turnover	7.35	7.04	7.66	7.37	7.49	6.61	7.81	7.65	7.29	6.64
Inventory Turnover	0.85	0.89	0.89	0.92	1.09	1.15	1.14	1.21	1.24	1.29
Fixed Asset Turnover	10.79	11.29	12.20	13.26	14.43	15.75	16.76	21.73	22.50	24.16
Accounts Payable Turnover	3.68	8.26	5.29	6.43	5.92	11.01	6.24	7.11	5.28	8.18
Days Sales Outstanding (DSO)	49.68	51.83	47.62	49.53	48.74	55.23	46.74	47.71	50.08	54.94
Days Inventory Outstanding (DIO)	428.49	408.06	410.46	397.56	334.67	318.78	319.36	301.10	294.71	281.93
Days Payable Outstanding (DPO)	99.32	44.18	68.95	56.77	61.63	33.14	58.54	51.31	69.16	44.59
Cash Conversion Cycle (CCC)	378.85	415.70	389.14	390.32	321.78	340.87	307.56	297.50	275.63	292.27
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	24	24	25	23	23	24	27	24	23	21
Invested Capital Turnover	2.52	2.46	2.37	2.66	2.77	2.87	2.78	3.28	3.44	3.72
Increase / (Decrease) in Invested Capital	6.22	4.42	2.61	0.56	-0.74	-0.21	1.58	0.47	0.13	-2.58
Enterprise Value (EV)	481	185	302	384	290	394	272	168	254	204
Market Capitalization	621	315	421	495	393	488	355	246	325	268
Book Value per Share	$4.39	$4.12	$3.82	$3.55	$3.31	$3.09	$2.86	$2.61	$2.40	$2.17
Tangible Book Value per Share	$4.32	$4.05	$3.76	$3.48	$3.24	$3.03	$2.80	$2.55	$2.34	$2.11
Total Capital	181	171	181	171	163	156	148	138	131	123
Total Debt	17	17	37	37	37	37	37	37	37	37
Total Long-Term Debt	12	17	37	37	37	35	32	37	37	34
Net Debt	-140	-130	-118	-111	-103	-94	-83	-78	-71	-65
Capital Expenditures (CapEx)	0.28	0.18	0.06	0.05	0.49	0.20	0.45	0.47	0.42	0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	9.34	9.18	11	9.38	10	12	16	15	15	13
Debt-free Net Working Capital (DFNWC)	166	151	164	145	127	129	132	130	123	115
Net Working Capital (NWC)	161	150	164	145	127	127	127	130	123	112
Net Nonoperating Expense (NNE)	4.42	4.04	4.38	4.69	4.28	4.14	3.57	4.39	4.25	3.78
Net Nonoperating Obligations (NNO)	-140	-130	-118	-111	-103	-94	-83	-78	-71	-65
Total Depreciation and Amortization (D&A)	0.32	0.25	0.24	0.19	0.17	-0.03	0.05	-0.06	-0.02	-0.04
Debt-free, Cash-free Net Working Capital to Revenue	17.98%	17.11%	19.58%	15.47%	15.82%	17.59%	21.24%	19.78%	18.53%	15.81%
Debt-free Net Working Capital to Revenue	320.47%	280.55%	286.19%	239.05%	195.87%	188.45%	180.66%	169.69%	154.76%	137.23%
Net Working Capital to Revenue	310.76%	280.39%	286.04%	238.90%	195.73%	185.31%	173.50%	169.57%	154.64%	133.44%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.38)	($0.38)	($0.42)	($0.43)	($0.39)	($0.36)	($0.36)	($0.39)	($0.36)	($0.33)
Adjusted Weighted Average Basic Shares Outstanding	37.19M	37.10M	37.57M	37.82M	38.12M	37.97M	38.64M	38.94M	39.28M	39.11M
Adjusted Diluted Earnings per Share	($0.38)	($0.38)	($0.42)	($0.43)	($0.39)	($0.36)	($0.36)	($0.39)	($0.36)	($0.33)
Adjusted Weighted Average Diluted Shares Outstanding	37.19M	37.10M	37.57M	37.82M	38.12M	37.97M	38.64M	38.94M	39.28M	39.11M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.41M	37.65M	37.75M	38.03M	38.31M	38.54M	38.82M	39.15M	39.49M	39.80M
Normalized Net Operating Profit after Tax (NOPAT)	-9.75	-10	-11	-12	-11	-9.74	-10	-11	-9.89	-9.39
Normalized NOPAT Margin	-72.22%	-66.38%	-78.98%	-66.93%	-60.13%	-50.54%	-53.97%	-52.62%	-48.51%	-39.52%
Pre Tax Income Margin	-104.96%	-91.00%	-108.26%	-93.38%	-84.00%	-70.75%	-71.94%	-73.34%	-68.44%	-55.28%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-50.22	-40.18	-28.53	-19.21	-17.29	-15.79	-15.99	-17.57	-16.08	-15.84
NOPAT to Interest Expense	-34.10	-28.52	-20.11	-13.32	-11.90	-10.78	-11.52	-12.27	-11.10	-11.15
EBIT Less CapEx to Interest Expense	-51.20	-40.67	-28.64	-19.28	-17.84	-16.01	-16.50	-18.10	-16.55	-15.98
NOPAT Less CapEx to Interest Expense	-35.07	-29.01	-20.21	-13.38	-12.45	-11.00	-12.03	-12.80	-11.57	-11.29
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Pulmonx Corp (NASDAQ:LUNG) shows improving top-line momentum in late 2024, with solid gross margins and substantial liquidity on the balance sheet. However, the company continues to post quarterly net losses and negative cash flow from operations, signaling ongoing profitability and cash-burn challenges despite favorable liquidity from investing activities and modest financing activity.

Q4 2024 revenue rose to $23.765 million, up from $20.387 million in Q3 2024.
Q4 2024 gross profit reached $17.59 million, up from $15.03 million in Q3 2024.
Gross margin remains strong in the ~73–75% range across 2024 quarters (roughly 73.6%–73.9%).
Q4 2024 cash flow from continuing investing activities was +$14.07 million, driven by the sale/maturity of investments.
Q4 2024 net change in cash and equivalents was +$7.59 million, reflecting improved liquidity for the period.
Balance sheet liquidity remains solid, with cash plus short-term investments around $107–108 million in mid-2024 (e.g., about $63.3 million cash and $44.5 million in short-term investments in Q3 2024).
Over the four reported years, revenue rose from about $15.4 million in Q4 2022 to about $23.8 million in Q4 2024, indicating top-line growth despite ongoing losses.
Gross margin has been relatively stable in the low–mid 70s percentage range across 2024 quarters, suggesting consistent product margins even as the company incurs operating costs.
Net income attributable to common shareholders was -$13.18 million in Q4 2024, signaling ongoing losses.
Operating cash flow remained negative across 2024 (Q4: -$6.73 million; Q3: -$7.24 million; Q2: -$5.77 million; Q1: -$11.80 million), indicating continued cash burn from core operations.

05/14/26 10:40 PM ETAI Generated. May Contain Errors.

Pulmonx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Pulmonx's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

Pulmonx's net income appears to be on a downward trend, with a most recent value of -$56.39 million in 2024, falling from -$58.92 million in 2022. The previous period was -$60.84 million in 2023. View Pulmonx's forecast to see where analysts expect Pulmonx to go next.

Pulmonx's total operating income in 2024 was -$57.70 million, based on the following breakdown:

Total Gross Profit: $62.00 million
Total Operating Expenses: $119.71 million

Over the last 2 years, Pulmonx's total revenue changed from $53.66 million in 2022 to $83.79 million in 2024, a change of 56.1%.

Pulmonx's total liabilities were at $77.04 million at the end of 2024, a 29.6% increase from 2023, and a 94.2% increase since 2022.

In the past 2 years, Pulmonx's cash and equivalents has ranged from $70.91 million in 2024 to $101.74 million in 2022, and is currently $70.91 million as of their latest financial filing in 2024.

Over the last 2 years, Pulmonx's book value per share changed from 4.12 in 2022 to 2.17 in 2024, a change of -47.2%.

Related Companies

Financial statements for NASDAQ:LUNG last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmonx (LUNG) Financials

Financials Breakdown Chart

Key Financial Trends

Pulmonx Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulmonx (LUNG) Financials

Annual Income Statements for Pulmonx

Quarterly Income Statements for Pulmonx

Annual Cash Flow Statements for Pulmonx

Quarterly Cash Flow Statements for Pulmonx

Annual Balance Sheets for Pulmonx

Quarterly Balance Sheets for Pulmonx

Annual Metrics And Ratios for Pulmonx

Quarterly Metrics And Ratios for Pulmonx

Financials Breakdown Chart

Key Financial Trends

Pulmonx Financials - Frequently Asked Questions

When does Pulmonx's fiscal year end?

How has Pulmonx's net income changed over the last 2 years?

What is Pulmonx's operating income?

How has Pulmonx's revenue changed over the last 2 years?

How much debt does Pulmonx have?

How much cash does Pulmonx have?

How has Pulmonx's book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools